Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 20/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 20/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 20/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 20/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 0.52 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420632 | 0.83 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4420734 | 0.82 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6847369 | 0.82 | SCN9A (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6847361 | 0.79 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6307844 | 0.75 | PSEN1 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4989540 | 0.74 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6307501 | 0.73 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4424166 | 0.73 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4413141 | 0.73 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4413546 | 0.73 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6774125-B2 | TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. | 2004-08-10 | — | — | US | disclosed |
| US-20030153550-A1 | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | AUDIA JAMES E (US) | 2003-08-14 | — | — | US | disclosed |
| US-6509331-B1 | Bicyclic amides such as 5-('-(2S-hydroxy-3-methylbutyrl)-2S-aminopropyl)amino-7-methyl-5,7-dihydro -6H-dibenz(b,d)azepin-6-one | ELAN PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | disclosed |
| EP-1089981-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS. | Elan Pharmaceuticals, Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1042298-A1 | POLYCYCLIC ALPHA-AMINO-EPSILON-CAPROLACTAMS AND RELATED COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999067220-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999032453-A1 | POLYCYCLIC α-AMINO-⊂-CAPROLACTAMS AND RELATED COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153550-A1 | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | APP, IAPP, BACE1 | PSEN1 5/4885PSEN2 6/4885APH1B 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.